leisure time -WSS

leisure time

author：leisure time 2025-08-19 18:06:59 - browse：93

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Microsoft's Peter Lee: Generative AI could help doctors be more human

WSS

Streamlined flu vaccines recommended by FDA advisory panel

Idaho college killings prosecutors challenge defense's grand jury claims

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

For AI in health care standards, federal regulators join with industry group

Ancient Greek ideas underpin modern concepts of pregnancy

Immune cells and nerve overgrowth may explain recurring UTI pain

entertainment

leisure time

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Patients, digital health players weigh in on FTC's data privacy plan

Dobbs anniversary: the lost opportunity of abortion as health care

Why Talkspace is targeting Medicare, a tricky market

Activists slam private health insurers over coverage restrictions

Patients, digital health players weigh in on FTC's data privacy plan

Wildfire smoke exposes gaps in outdoor worker protections

What to know about the judge who will handle the Trump case

FDA approval of Sarepta Duchenne genetic therapy gives me hope

For AI in health care standards, federal regulators join with industry group

knowledge

Bird flu researchers hone in on Finland’s mink farms

Readout Newsletter: BridgeBio, Akero, and human embryo models

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Timeline: How the deadly wildfires took over Maui day by day

Hospitals are dialing back on venture capital investing

Patients, digital health players weigh in on FTC's data privacy plan

focus

Wikipedia

explore

hotspot